The FDA has approved a higher weekly dose of Wegovy (semaglutide) at 7.2 mg. While clinical trials show this 3× increase can drive total body weight loss toward 20.7%, it also raises the risk of dose-dependent side effects like dysesthesia and GI distress. With no official titration guidelines yet available, Dr. Joshua Silva discusses how to approach this new dosage safely and who may benefit most from the increase.